Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ACETASOL HC vs ACTICORT
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Acetic acid (otic solution) is antibacterial and antifungal; hydrocortisone is a corticosteroid that suppresses inflammation.
Topical corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive actions. Suppresses cytokine production and inflammatory mediators via glucocorticoid receptor binding.
Treatment of superficial bacterial infections of the external auditory canal (swimmer's ear),Treatment of fungal infections of the external ear
Corticosteroid-responsive dermatoses (e.g., eczema, psoriasis, contact dermatitis),Off-label: atopic dermatitis, lichen planus, discoid lupus erythematosus
5 drops into the affected ear(s) 3-4 times daily. Each drop contains 2% acetic acid and 1% hydrocortisone.
5-60 mg orally once daily, or divided twice daily, depending on condition severity and response.
Hydrocortisone has a terminal elimination half-life of approximately 1.5-2 hours. Acetic acid has a half-life of minutes due to rapid metabolism. Clinical context: dosing interval is typically 3-4 times daily for otic use.
1.5-2.5 hours; prolonged in hepatic impairment (up to 10 hours) and renal impairment (up to 6 hours)
Not extensively metabolized; undergoes minimal hepatic metabolism.
Hepatic metabolism via CYP3A4; inactive metabolites excreted renally and biliary.
Acetasol HC is a combination product containing hydrocortisone and acetic acid. Hydrocortisone is primarily metabolized in the liver and excreted renally as inactive metabolites; less than 1% is excreted unchanged. Acetic acid is rapidly metabolized via the tricarboxylic acid cycle and eliminated as carbon dioxide and water. Biliary/fecal elimination is negligible for both components.
Renal (70% as unchanged drug and metabolites), biliary/fecal (30%)
Hydrocortisone is approximately 90-95% bound to corticosteroid-binding globulin (CBG) and albumin. Acetic acid has negligible protein binding (<10%).
90% bound to albumin and corticosteroid-binding globulin
Hydrocortisone Vd is approximately 0.3-0.5 L/kg, indicating distribution into total body water. Acetic acid Vd is approximately 0.4 L/kg. Clinical meaning: limited tissue distribution; primarily remains in extracellular fluid.
1.2-1.5 L/kg; indicates extensive tissue distribution
Otic: Bioavailability is approximately 10-20% via the ear canal due to slow permeation through tympanic membrane; systemic absorption is minimal (<10% of applied dose). Oral: Not applicable; product is for otic use only.
Oral: 80-90%; IM: 100%
No renal adjustment required as systemic absorption is negligible.
No dose adjustment necessary for acute use; for chronic therapy in severe renal impairment (e GFR <30 m L/min/1.73 m2), consider dose reduction by 50% to minimize mineralocorticoid effects.
No hepatic adjustment required as systemic absorption is negligible.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use or reduce dose by 75% due to reduced clearance.
Same as adult: 5 drops into affected ear(s) 3-4 times daily. Safety and efficacy in children under 2 years not established.
0.05-2 mg/kg/day orally divided every 6-8 hours, not to exceed 80 mg/day; adjust based on response and severity.
No specific adjustment; use same adult dosing. Consider age-related skin thinning and potential for increased systemic absorption in cases of tympanic membrane perforation.
Initiate at lowest effective dose (e.g., 5 mg/day) and titrate slowly due to increased risk of osteoporosis, glucose intolerance, and immunosuppression; monitor for adverse effects.
None
None
For otic use only; not for ophthalmic use,Prolonged use may result in overgrowth of non-susceptible organisms,Discontinue if sensitization or irritation occurs,Caution in patients with perforated tympanic membrane
HPA axis suppression with prolonged use or large surface area,Local irritation and skin atrophy,Systemic absorption with occlusive dressings,Potential for rebound effects after discontinuation
Hypersensitivity to any component,Perforated tympanic membrane,Viral or fungal infections of the ear (except when used for fungal infections as indicated)
Known hypersensitivity to components,Untreated bacterial/fungal infections,Viral skin infections (e.g., herpes simplex, varicella),Perioral dermatitis, rosacea
No known food interactions. Avoid excessive alcohol as it may impair immune response.
No clinically significant food interactions. Alcohol may increase systemic absorption if tympanic membrane is perforated, but generally avoid alcohol-based ear drops if perforation suspected.
ACETASOL HC (hydrocortisone 1% and acetic acid 2%) is an otic solution. Systemic absorption following topical otic application is minimal. No adequate and well-controlled studies in pregnant women. Animal reproduction studies with topical glucocorticoids have shown an increased risk of cleft palate and other malformations at high doses. Based on limited human data and low systemic exposure, use during pregnancy is generally considered low risk. However, as a precaution, avoid use in the first trimester unless clearly needed.
First trimester: Increased risk of cleft palate and cardiac defects (OR 1.3-3.5). Second/third trimesters: Risk of fetal growth restriction, adrenal suppression, and oligohydramnios with chronic use. Avoid use unless maternal benefit outweighs risks.
Systemic absorption after otic application is minimal. It is not known whether hydrocortisone or acetic acid is excreted in human milk. M/P ratio is not available. Concentrations in milk are likely negligible. Use is considered compatible with breastfeeding.
Prednisone enters breast milk at low levels (M/P ratio ~0.1-0.3). At maternal doses ≤20 mg/day, the infant dose is <10% of maternal weight-adjusted dose. Consider risk of adrenal suppression in infant with high-dose, long-term therapy. AAP rates as compatible with breastfeeding.
No dose adjustment is necessary in pregnancy due to minimal systemic absorption. Pharmacokinetic changes in pregnancy are not expected to alter efficacy or safety of this topical otic preparation.
No empirical dose adjustment required; however, pharmacokinetic changes (increased Vd, hepatic metabolism) may reduce efficacy. Doses may need to be increased by 20-30% in third trimester if disease activity increases. Taper to lowest effective dose.
ACETASOL HC (acetic acid 2%, hydrocortisone 1%) is used for otitis externa. Acetic acid restores acidic p H of ear canal, inhibiting bacterial and fungal growth. Hydrocortisone reduces inflammation and pruritus. Ensure tympanic membrane is intact before use due to risk of ototoxicity with corticosteroids in middle ear. Do not use for more than 7 days. Shake well before instillation.
ACTICORT (hydrocortisone/neomycin/polymyxin B) is a topical combination used for inflammatory ear conditions. Avoid prolonged use (>10 days) to prevent sensitization and overgrowth of non-susceptible organisms. Tympanic membrane perforation is a contraindication due to ototoxicity risk. Use the otic solution not the ophthalmic suspension for ear infections.
Instill 3-4 drops into affected ear every 2-3 hours for 5-7 days.,Lie on side for 5 minutes after instillation to ensure coverage.,Avoid inserting cotton swabs or objects into the ear.,Discontinue if pain, worsening discharge, or rash occurs.,Do not use if ear drum is perforated or if you have a history of ear surgery.
Instill drops while lying down with affected ear upward, then remain in position for 5 minutes.,Do not touch dropper to ear or any surface to avoid contamination.,Complete full course even if symptoms improve; do not use longer than prescribed.,Report worsening redness, swelling, or hearing loss immediately.,Avoid getting water in ear during treatment; use a cotton ball soaked in petroleum jelly to protect ear when showering.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ACETASOL HC vs ACTICORT, answered by our medical review team.
ACETASOL HC is a Otic Anti-infective with Corticosteroid that works by Acetic acid (otic solution) is antibacterial and antifungal; hydrocortisone is a corticosteroid that suppresses inflammation.. ACTICORT is a Corticosteroid that works by Topical corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive actions. Suppresses cytokine production and inflammatory mediators via glucocorticoid receptor binding.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ACETASOL HC and ACTICORT depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ACETASOL HC is: 5 drops into the affected ear(s) 3-4 times daily. Each drop contains 2% acetic acid and 1% hydrocortisone.. The standard adult dose of ACTICORT is: 5-60 mg orally once daily, or divided twice daily, depending on condition severity and response.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ACETASOL HC and ACTICORT in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ACETASOL HC is classified as Category C. ACETASOL HC (hydrocortisone 1% and acetic acid 2%) is an otic solution. Systemic absorption following topical otic application is minimal. No adequate and well-controlled studies i. ACTICORT is classified as Category C. First trimester: Increased risk of cleft palate and cardiac defects (OR 1.3-3.5). Second/third trimesters: Risk of fetal growth restriction, adrenal suppression, and oligohydramnio. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.